Bioventus Inc. will report Q4 2025 financial results on March 5, 2026, followed by a conference call.
Quiver AI Summary
Bioventus Inc. announced that it will release its financial results for the fourth quarter of fiscal year 2025 on March 5, 2026, before the market opens. Following the results, the company's management will hold a conference call at 8:30 a.m. Eastern Time to discuss the financials and provide a business update. Interested participants can join the call by dialing 1-833-636-0497, and a live webcast will be available on the company's Investor Relations section of their website. The webcast will be archived for replay until March 4, 2027. Bioventus focuses on delivering innovative and effective products for healing, including pain treatments, restorative therapies, and surgical solutions, and is committed to high quality standards and ethical practices.
Potential Positives
- Bioventus is scheduled to report its financial results for Q4 FY 2025, indicating transparency and accountability in its financial reporting practices.
- The upcoming conference call demonstrates the company's commitment to engaging with investors and stakeholders by providing updates and insights into its business performance.
- The archived webcast availability for a year enhances accessibility for investors who may not be able to attend the live event, reflecting the company’s commitment to investor relations.
Potential Negatives
- None
FAQ
When will Bioventus report its financial results for Q4 2025?
Bioventus will report its financial results for the fourth quarter of fiscal year 2025 on March 5, 2026.
What time is the Bioventus conference call scheduled?
The conference call is scheduled for 8:30 a.m. Eastern Time on March 5, 2026.
How can I join the Bioventus conference call?
You can join by dialing 1-833-636-0497 and referring to the Bioventus Inc. Conference Call.
Where can I find the webcast of the Bioventus conference call?
The webcast will be available in the “Investor Relations” section of Bioventus' website.
How long will the Bioventus conference call replay be available?
The replay of the conference call will be available until March 4, 2027.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BVS Insider Trading Activity
$BVS insiders have traded $BVS stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BVS stock by insiders over the last 6 months:
- MICHELLE MCMURRY-HEATH sold 17,701 shares for an estimated $131,254
- GUY P NOHRA sold 10,000 shares for an estimated $75,658
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BVS Revenue
$BVS had revenues of $138.7M in Q3 2025. This is a decrease of -0.23% from the same period in the prior year.
You can track BVS financials on Quiver Quantitative's BVS stock page.
$BVS Hedge Fund Activity
We have seen 84 institutional investors add shares of $BVS stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE PR LLC added 650,164 shares (+185.7%) to their portfolio in Q3 2025, for an estimated $4,349,597
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 512,386 shares (-73.7%) from their portfolio in Q4 2025, for an estimated $3,812,151
- ESSEX INVESTMENT MANAGEMENT CO LLC added 387,886 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,885,871
- MEROS INVESTMENT MANAGEMENT, LP added 315,160 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,344,790
- SEGALL BRYANT & HAMILL, LLC removed 281,849 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,885,569
- HILLSDALE INVESTMENT MANAGEMENT INC. added 269,909 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,008,122
- AMERICAN CENTURY COMPANIES INC removed 243,297 shares (-22.3%) from their portfolio in Q4 2025, for an estimated $1,810,129
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/ . The webcast will be archived at the same site and available for replay until March 4, 2027.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit
www.bioventus.com
and follow the Company on
LinkedIn
and
X
. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
[email protected]
